Intangible Assets (Tables)
|9 Months Ended|
Sep. 30, 2023
|Goodwill and Intangible Assets Disclosure [Abstract]|
|Schedule of Intangible Assets||
Intangible assets as of September 30, 2023 and December 31, 2022 consist of the following (in $000’s):
*The Soin intangibles acquired by the Company consist of the following:
1.Three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain;
2.Final formula for Naltrexone; and
3.Orphan drug designation as approved by the FDA.
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef